ConcertAI, a leader in oncology-focused AI SaaS and multi-modal data solutions, has appointed Michael Myshrall as Chief Financial Officer to steer its financial strategy and support its growth in AI-driven healthcare innovation. This move strengthens ConcertAI’s position as a pioneer in advancing clinical research and patient care.
ConcertAI appoints Michael Myshrall as Chief Financial Officer.
Myshrall brings over 20 years of experience in SaaS and AI sectors.
Previously CFO at Afiniti, Cyren, and PrimePay, driving financial growth.
Expertise in scaling SaaS models and optimizing recurring revenue.
Appointment supports ConcertAI’s expansion in oncology AI solutions.
Myshrall to lead financial strategy for drug discovery and patient care.
ConcertAI has named Michael Myshrall as its Chief Financial Officer, leveraging his extensive experience in financial leadership within SaaS, AI, and technology sectors. “Mike’s proven track record of driving financial excellence and operational scale makes him the ideal leader to guide ConcertAI through our next phase of growth,” said Eron Kelly, Chief Executive Officer of ConcertAI. “His deep understanding of SaaS models, combined with his experience in AI and technology sectors, aligns perfectly with our mission to accelerate breakthroughs in life sciences and healthcare through innovative AI solutions.”
Myshrall joins ConcertAI from Afiniti, a leader in customer experience AI software, where he led an international finance organization and navigated a complex financial recapitalization. Prior roles include CFO at Cyren, a NASDAQ-listed cybersecurity firm, where he raised over $100 million in capital, including a majority sale to Warburg Pincus, and at PrimePay, a private-equity-backed human capital management software company. His expertise spans SaaS business models, recurring revenue optimization, and financial metrics critical for scaling AI-driven healthcare technologies.
Myshrall’s appointment aligns with ConcertAI’s expansion of its platform, which integrates real-world data, AI innovation, and clinical expertise to transform drug discovery, clinical trials, and patient care delivery. A Harvard Business School MBA graduate, Myshrall has a robust history of leading mergers, acquisitions, and capital-raising efforts, positioning him to enhance ConcertAI’s financial strategy and operational efficiency.
ConcertAI’s solutions serve major pharmaceutical companies and leading healthcare institutions worldwide, driving advancements in oncology research and care. Myshrall’s financial leadership will support the company’s mission to accelerate breakthroughs, ensuring scalable and sustainable growth in the competitive healthcare AI landscape.
This strategic appointment positions ConcertAI to further its leadership in oncology-focused AI solutions, leveraging Myshrall’s expertise to drive financial excellence and innovation in healthcare.
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.